Novel classes of biological agents, including TNF-α antagonists and IL-1 antagonists, provide a favorable opportunity for anti-RA with a lower risk of side effects and remarkable treatment results (Ding et al., 2015). This evidence concerns the gene IL1B and rheumatoid arthritis.